We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Novel Vaccine Could Simultaneously Target Multiple Viral Infections

By LabMedica International staff writers
Posted on 26 Sep 2017
A novel vaccine designed to prevent infection by several different viruses simultaneously in based on ability of a receptor protein on the surface of immune cells to recognize a common, invariable viral antigen.

Killer-cell immunoglobulin-like receptors (KIRs), are a family of type I transmembrane glycoproteins expressed on the plasma membrane of natural killer (NK) cells and a minority of T-cells. More...
These receptors regulate the killing function of these cells by interacting with major histocompatibility (MHC) class I molecules, which are expressed on all nucleated cell types. KIR receptors can distinguish between major histocompatibility (MHC) class I allelic variants, which allows them to detect virally infected cells or transformed cells. Most KIRs are inhibitory, suppressing the cytotoxic activity of their NK cell. Only a limited number of KIRs are activating, meaning that their recognition of MHC molecules activates the cytotoxic activity of their cell. As a result of KIR's role in killing unhealthy self-cells and not killing healthy self-cells, KIRs are involved in protection against and propensity to viral infection, autoimmune disease, and cancer.

Investigators at the University of Southampton (United Kingdom) worked with the killer cell immunoglobulin-like receptor KIR2DS2. They singled out this important receptor protein for further study after analyzing DNA from more than 300 patients exposed to the hepatitis C virus and finding that the KIR2DS2 receptor was associated with successfully clearing the virus. In addition, they showed that KIR2DS2 directly recognized viral peptides derived from conserved regions of the NS3 helicase enzyme from the flaviviral superfamily (hepatitis C virus, Zika virus, dengue virus, yellow fever virus, Japanese encephalitis virus, etc.) in the context of major histocompatibility complex class I.

The investigators reported in the September 15, 2017, online edition of the journal Science Immunology that the peptide LNPSVAATL from the hepatitis C virus (HCV) helicase bound the human leukocyte antigen (HLA) allele HLA-C*0102, leading to NK cell activation through engagement of KIR2DS2. However, while this region was highly conserved across HCV isolates, the sequence was not present in other flaviviral helicases. They then identified a distinct peptide, MCHAT, which was sensed by KIR2DS2 and was conserved in a number of flaviviruses including dengue, Zika, and yellow fever viruses.

Senior author Dr. Salim Khakoo, professor of hepatology at the University of Southampton, said, "The NS3 helicase protein could be the key in unlocking the defense of lethal viruses that affect so many people around the world. It is very exciting to discover that other viruses similar to hepatitis C, such as Zika virus, dengue virus, yellow fever virus, Japanese encephalitis virus and in fact all flaviviruses, contain a region within their NS3 helicase proteins that is recognized by exactly the same KIR2DS2 receptor. We believe that by targeting this NS3 helicase region, we could make a new type of vaccine based upon natural killer cells, which can be used to help protect people from these infections."

Related Links:
University of Southampton


Gold Member
Veterinary Hematology Analyzer
Exigo H400
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.